![]() ![]() AKT1 is a serine-threonine kinase that participates in the AKT/PI3K/mTOR pathway: The p.Glu17Lys variant constitutively activates the protein, limiting apoptosis and promoting growth, among other effects ( Carpten et al. It makes weight-bearing and footwear uncomfortable, and hygiene is difficult to maintain ( Cohen 2014).Ī somatic variant in the AKT1 gene-c.49G > A, p.Glu17Lys-is the only reported cause of PS ( Lindhurst et al. The cerebriform connective tissue nevus (CCTN) of the soles found in many patients is a specific, but not pathognomonic finding. Common syndromic manifestations include large superficial or deep lipomatous overgrowths, intellectual disability, seizures and other neurological problems, and severe skeletal deformities with skull overgrowth, kyphoscoliosis, asymmetric macrodactyly and valgus, or varus deformities of the knees. 2011), or malignant transformation in an overgrown tissue such as a parotid tumor, ovarian cystadenoma, or testicular tumor ( Cohen 2005). 2017), respiratory disease associated with pulmonary cysts ( Newman et al. 2017), either by distortion or compression of vital structures by overgrown tissues, thromboembolism ( Keppler-Noreuil et al. It is progressive and causes death ( Sapp et al. Patients with Proteus syndrome (PS) have severe, progressive overgrowth that can affect nearly any region of the body ( Biesecker 2006). We conclude that 1 yr of treatment with miransertib was beneficial in this case. Whole-body MRI findings were stable without apparent disease progression. After 11 mo of treatment, the patient reported improved general well-being, increased mobility of the ankle, spine, and hands, a subjective decrease in size of the right facial bone overgrowth, and reduced areas of cerebriform connective tissue nevi on the soles. Adverse events included dry mouth, one episode of gingivostomatitis, and loose, painful dentition due to preexisting periodontal disease, all of which resolved spontaneously. After baseline evaluation, the patient started unblinded treatment of 10 mg oral miransertib daily (∼5 mg/m 2/day), escalated to 30 mg daily (∼15 mg/m 2/day), and then to 50 mg daily (∼25 mg/m 2/day) after 3 mo of treatment. ![]() Miransertib (ARQ 092) is an oral, allosteric, selective pan-AKT inhibitor initially developed for cancer therapeutics, now being evaluated for the treatment of PS. A 20-yr-old man with Proteus syndrome (PS) and somatic mosaicism of the AKT1 c.49G > A p.(E17K) variant had asymmetric overgrowth of the right frontal and facial bones, asymmetric spinal overgrowth with thoracolumbar scoliosis, dilatation of the inferior vena cava, testicular cystadenoma, bilateral knee deformities, macrodactyly, and apparent intellectual disability.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |